Effect of letrozole on the lipid profile in postmenopausal women with breast cancer

Elisaf, Moses; Bairaktari, Eleni; Nicolaides, C.; Kakaidi, Barbara; Tzallas, C.; Katsaraki, Afroditi; Pavlidis, Nicholas

doi:10.1016/s0959-8049(01)00155-1

Cited by 134 publications

(51 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In contrast, the estrogen-lowering effects of aromatase inhibitors have an adverse effect on blood lipids, according to a small, short-term study (Elisaf et al 2001). The available data are insufficient to evaluate the long-term effects discussed.…”

Section: Cardiovascular Effectsmentioning

confidence: 99%

Effects of estrogen deprivation due to breast cancer treatment

Angelopoulos¹,

Barbounis²,

Livadas³

et al. 2004

Endocr Relat Cancer

View full text Add to dashboard Cite

Breast cancer is one of the main life-threatening diseases that a woman may have to face during her lifetime. The increasing incidence of breast neoplasia reported over the last few decades has led to widespread screening of women resulting in early diagnosis. One common but challenging question for most doctors, after the surgical excision of the lesion, is determination of the ideal adjuvant therapy for their patients for the achievement of maximum life expectancy with the best quality of life.Since the beginning of the last century, the knowledge that breast cancer arises from hormoneresponsive tissues has long made use of hormone-blocking agents in the beneficial treatment of breast neoplasia. The discovery of new molecules with endocrine actions has rendered the use of adjuvant therapy in a tailor-made pattern too complicated, as these agents have a different mode of action, different adverse effects and probably different indications.The aim of the present review is to clarify these issues, analyzing the mechanism of action of available drugs and their actions on specific areas of uncertainty: cognitive function, cardiovascular system, urogenital tract, bone metabolism, weight gain, hot flushes and premature menopause. Regarding the efficacy of adjuvant therapy, there has been particular focus on the multiple hormonal-induced consequences of each regimen in order to provide the clinician with the available data for choosing the ideal therapy for the patient.

show abstract

Section: Cardiovascular Effectsmentioning

confidence: 99%

Effects of estrogen deprivation due to breast cancer treatment

Angelopoulos¹,

Barbounis²,

Livadas³

et al. 2004

Endocr Relat Cancer

View full text Add to dashboard Cite

show abstract

“…The ASCO technical review and the St Gallen Consensus Panel continue to emphasise the lack of safety data regarding long-term oestrogen deprivation. For example, AIs have been reported to alter cholesterol and lipoprotein metabolism with potentially deleterious effects on cardiovascular health (Elisaf et al, 2001). There are also concerns about the effects of long-term oestrogen deprivation on memory and risk for dementia.…”

Section: Toxicity and Tolerabilitymentioning

confidence: 99%

First-line endocrine treatment of breast cancer: aromatase inhibitor or antioestrogen?

Ellis

2004

Br J Cancer

View full text Add to dashboard Cite

Until recently, endocrine therapy for breast cancer was relatively simple. If the tumour expressed hormone receptors, regardless of stage and age, tamoxifen was indicated. While this largely remains the case for premenopausal women, clinical trials in postmenopausal women have broadened our choice to include one of three selective aromatase inhibitors (AIs), the nonsteroidal agents anastrozole or letrozole and the steroidal agent exemestane. Comparative data concerning the efficacy, toxicity, tolerability and cost of AI vs tamoxifen continues to evolve with over 40 000 women slated to be involved in clinical trials. Currently, tamoxifen remains an appropriate choice for adjuvant treatment, and will remain so unless a clear survival advantage emerges for adjuvant AI therapy. However, anastrozole is widely seen as a useful alternative, with particular merit for patients prone to the development of serious tamoxifen side effects. For endocrine therapy naïve advanced disease, several trials have provided evidence that a nonsteroidal AI has replaced tamoxifen as optimal treatment. In the neoadjuvant setting, letrozole was also more effective than tamoxifen, both in terms of response rates and the incidence of breast-conserving surgery, and so AI therefore also dominates this evolving indication. The ongoing adjuvant clinical trials ask all the relevant questions regarding tamoxifen and AI in combination, sequence and duration, except for 5 years of an AI vs a longer period. For both the advanced and early-stage disease, resistance remains the key obstacle to overcome, and trials that combine endocrine agents with signal transduction inhibitors such as HER1 and HER2 kinase inhibitors, farnesyl transferase inhibitors, mTOR inhibitors as well as COX2 inhibitors are being developed in a concerted attempt to address this problem.

show abstract

“…Participants given letrozole only did displayed more incidences of skeletal and cardiac events and hypercholesterolemia compared to the tamoxifen group [37]. After letrozole treatment, unfavorable effects have been seen including increased serum total cholesterol, LDL and ApoB with atherogenic ratio risk of total cholesterol/HDL and LDL/HDL levels (Table 1) [39]. Therefore, the better cognitive outcomes may not out-weigh negative effects on lipoprotein levels, particularly in those with or at risk for hypertension and/or diabetes.…”

Section: Letrozolementioning

confidence: 99%

The Confounding Factor of Apolipoprotein E on Response to Chemotherapy and Hormone Regulation Altering Long-Term Cognition Outcomes

Acevedo¹

2012

Lipoproteins - Role in Health and Diseases

View full text Add to dashboard Cite

Effect of letrozole on the lipid profile in postmenopausal women with breast cancer

Cited by 134 publications

References 16 publications

Effects of estrogen deprivation due to breast cancer treatment

Effects of estrogen deprivation due to breast cancer treatment

First-line endocrine treatment of breast cancer: aromatase inhibitor or antioestrogen?

The Confounding Factor of Apolipoprotein E on Response to Chemotherapy and Hormone Regulation Altering Long-Term Cognition Outcomes

Contact Info

Product

Resources

About